First Tracks Biotherapeutics, Inc.
TRAXDrugs in Pipeline
0
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Feb 28, 2027
27wMarket Overview
Stock performance and key metrics
4 upcoming, 1 past
No drugs found in this phase.
cancer
2 drugs in this indication
advanced GEP-NETs
1 drug in this indication
stem cell transplant preparation
1 drug in this indication
First-line unresectable hepatocellular carcinoma (HCC)
1 drug in this indication
First-line consolidation therapy in MRD-positive large B-cell lymphoma
1 drug in this indication
spinal cord injuries
1 drug in this indication
cholangiocarcinoma with acquired FGFR inhibitor resistance
1 drug in this indication
early-onset disc problems
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
When is First Tracks Biotherapeutics, Inc.'s next FDA catalyst?→
First Tracks Biotherapeutics, Inc.'s (TRAX) next tracked catalyst is a Phase 3 expected February 28, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track TRAX biotech catalysts?→
Add TRAX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow First Tracks Biotherapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.